Zirconium Zr 89 Crefmirlimab Berdoxam
Locally Advanced Solid Tumor
University Medical Center Groningenantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
53 Active assets in the Locally Advanced Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
vc004 Jiangsu vcare pharmaceutical technology co., LTD | Phase 3 | B |
Nivolumab Mohammed Milhem | Phase 2 | B |
TRASTUZUMAB Aiping Zhou | Phase 2 | B |
Eloxatin Parabilis Medicines, Inc. | Phase 2 | B |
S-1 Aiping Zhou | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
Zirconium Zr 89 Crefmirlimab Berdoxam is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →